Novartis AG (ADR) (NYSE:NVS) announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults from 10 years through 25 years of age. Novartis AG … Continue reading Hot Movers: Novartis AG (NYSE:NVS), IMAX Corporation (NYSE:IMAX), ImmunoGen (NASDAQ:IMGN), bluebird bio (NASDAQ:BLUE), Randgold Resources (NASDAQ:GOLD)